Table 9 Clinical outcomes by the selected studies Kidney and target therapy
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | Local Control | Distant progression free survival | Overall Survival | Toxicity |
|---|---|---|---|---|
Staehler 2011 [57] | 98% at 15 months | N.S. | 17.4 months (spinal lesions) 11.1 months (brain lesions) | 2 pts.: asymptomatic tumour haemorrhage after SRS (G2) 3 pts.: convulsions (G2) |
Staehler 2012 [58] | NS (1 case of PD at first evaluation at 3 months, other patients remission or stable disease) | N.S. | 65% at 2 years | No G3 during combination |
Cochran 2012 [50] | 74% at 1 year 40% at 3 years (better for combined therapy: 1 year LC was 93.3 and 60% for patients treated with and without targeted agents, respectively) | N.S. | 38% at 1 year, 9% at 3 years (median survival 16.6 months for pts. treated with target therapy) | 6 pts.: brain edema or necrosis (3 of them received target therapy) 2 brain hemorrhage |
Verma 2013 [51] | 75.6% at 1 year in pts. treated with SRS LC was statistically superior in lesions managed with surgery or SRS vs. the no local therapy. No improvement of LC with TKIs added to local therapy (surgery, SRS) | N.S. | 5.4 months (all pts) | 4 pts.: radionecrosis (2 of them in the TKI group and 2 in the non-TKI group) |
Bastos 2015 [59] | N.S. | N.S. | 12.2 months | 5 pts. (8%): neurological 2 pts.: brain necrosis 3 pts.: brain hemorrhage |
Miller 2016 [54] | Subgroup SRS + TKI: 94% at 1 year | N.S. | N.S. | No G3 in TKI + SRS pts., the incidence of post-SRS vertebral fracture (overall 21%) and pain flare (overall 17%) were similar across cohorts (TKI, SRS alone, TKI + SRS) |
Franzese 2019 [55] | 90.2% at 1 and 1.5 year | N.S. | 100% at 1 year 83% at 5 years | No G3 acute or late toxicity |